We are live on ! Find out more
BBH icon

VanEck Biotech ETF

59 hedge funds and large institutions have $151M invested in VanEck Biotech ETF in 2014 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 26 increasing their positions, 12 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

117% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 6

117% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 12

36% more capital invested

Capital invested by funds: $112M → $151M (+$39.7M)

13% more funds holding

Funds holding: 5259 (+7)

2.97% more ownership

Funds ownership: 23.41%26.38% (+3%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

2% less call options, than puts

Call options by funds: $4.56M | Put options by funds: $4.64M

Holders
59
Holders Change
+7
Holders Change %
+13.46%
% of All Funds
1.7%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
13
Increased
26
Reduced
12
Closed
6
Calls
$4.56M
Puts
$4.64M
Net Calls
-$81K
Net Calls Change
-$4.47M
Name Holding Trade Value Shares
Change
Change in
Stake
CS
1
Credit Suisse
Switzerland
$29.9M +$21.2M +218,422 +198%
Goldman Sachs
2
Goldman Sachs
New York
$16.1M +$12.2M +125,415 +245%
NCM
3
Niemann Capital Management
Nevada
$14.4M +$3.89K +40 +0%
U
4
UBS
Switzerland
$11.4M +$1.82M +18,769 +18%
Citigroup
5
Citigroup
New York
$9.32M +$204K +2,103 +2%
Morgan Stanley
6
Morgan Stanley
New York
$6.54M +$1.49M +15,378 +27%
Susquehanna International Group
7
Susquehanna International Group
Pennsylvania
$5.96M -$5.66M -58,276 -47%
MCM
8
Murphy Capital Management
New Jersey
$5.52M +$551K +5,666 +10%
LFM
9
Lumina Fund Management
New York
$3.76M
AHS
10
Aspiriant Holdings S3
California
$3.61M -$227K -2,340 -6%
TRCT
11
Tower Research Capital (TRC)
New York
$3.53M +$3.4M +35,018 +918%
CM
12
Churchill Management
California
$3.41M +$93.6K +963 +3%
WJA
13
Williams Jones & Associates
New York
$3.2M +$2.31M +23,800 +209%
VKH
14
Virtu KCG Holdings
New York
$3.13M +$3.34M +34,400 New
ECML
15
Eagle Capital Management (Louisiana)
Louisiana
$2.86M +$1.22M +12,576 +67%
LPL Financial
16
LPL Financial
California
$2.64M +$52.9K +544 +2%
AFG
17
Albion Financial Group
Utah
$2.14M +$119K +1,226 +6%
SFS
18
Strategic Financial Services
New York
$2.05M +$56.8K +584 +3%
Commonwealth Equity Services
19
Commonwealth Equity Services
Massachusetts
$1.81M +$386K +3,968 +25%
Creative Planning
20
Creative Planning
Kansas
$1.62M +$1.73M +17,806 New
Royal Bank of Canada
21
Royal Bank of Canada
Ontario, Canada
$1.5M -$96.6K -994 -6%
Verition Fund Management
22
Verition Fund Management
Connecticut
$1.45M +$1.55M +15,967 New
LTFS
23
Ladenburg Thalmann Financial Services
Florida
$1.3M +$182K +1,873 +15%
Ameriprise
24
Ameriprise
Minnesota
$1.26M +$505K +5,191 +60%
SC
25
Scotia Capital
Ontario, Canada
$1M +$1.07M +11,003 New

BBH Hedge Fund Activity: Q1 2014 in Review

59 of the 3,464 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q1 2014, worth a combined $151M — up 36% from $112M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new BBH positions and 6 closed out — a net gain of 7 holders — while 26 added to existing stakes and 12 trimmed.

The largest buyer was Credit Suisse, adding an estimated $21.2M. The largest seller was Bank of Montreal, cutting an estimated $5.97M.

  • 59 institutional investors held VanEck Biotech ETF (BBH) as of Q1 2014, up from 52 in Q4 2013.
  • Funds reported $151M of VanEck Biotech ETF stock for Q1 2014, up 36% quarter-over-quarter.
  • 13 funds opened new VanEck Biotech ETF positions in Q1 2014 and 6 closed out, a net change of +7 holders.
  • The largest VanEck Biotech ETF buyer in Q1 2014 was Credit Suisse, an estimated $21.2M added.
  • The largest VanEck Biotech ETF seller in Q1 2014 was Bank of Montreal, an estimated $5.97M sold.

Based on aggregated 13F filings for Q1 2014.